US Leads Cushing Syndrome Market Prevalent Cases to 2023 Says a New Report Available at RnRMarketResearch.com

News provided by

RnR Market Research

Oct 31, 2014, 17:30 ET

Dallas, Texas (PRWEB) November 01, 2014 -- Cushing’s syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, such as cortisol. Cortisol is a hormone produced by the adrenal glands that has many functions in the body, such as anti-inflammatory action, antiallergic action, antianabolic action, and amino acid catabolic action (Resmini, 2014). CS is associated with increased mortality caused by complications due to excess cortisol (Resmini, 2014). This epidemiological analysis focuses on CS, and four subtypes of CS: Cushing’s disease, ectopic-adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS.

Epidemiologists forecast an increase in the diagnosed prevalent cases of CS in the 6MM, from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed prevalent cases in 2023, with an annual growth rate (AGR) of 0.59%. In 2023, the US will have the highest number of diagnosed prevalent cases of CS, with 17,162 diagnosed prevalent cases. Additionally, each of the 6MM will see an increase in diagnosed prevalent cases over the 10-year forecast period, except for Germany, which will have a negative AGR of 0.14%. Because GlobalData epidemiologists applied a constant diagnosed prevalence in each of the 6MM, the trends in the diagnosed prevalent cases of CS are attributed to changing population demographics in the 6MM.

Complete report available @ http://www.rnrmarketresearch.com/epicast-report-cushings-syndrome-epidemiology-forecast-to-2023-market-report.html .

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to ≥85 years) and sex in these markets. Additionally, GlobalData epidemiologists provide the immediate outcome of transsphenoidal adenomectomy surgery (TSS) in patients with Cushing’s disease.

For this analysis, GlobalData epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM.

For this analysis, Epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM. The forecast provides the age- and sex-specific diagnosed prevalent cases of CS subtypes in the six markets, providing a comprehensive view of CS. In addition, this analysis provided detailed, clinically relevant segmentations for Cushing’s disease in order to improve the management of the disease.

Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235511 .

Scope

  • The Cushing’s syndrome (CS) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic- adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to =85 years) and sex in these markets.
  • The CS epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
  • The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=235511 . (This is a premium report priced at US$3995 for a single user License.)

Major Points in Table of Content
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.3.1 US
3.3.2 5EU
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods – Prevalent Cases
3.4.4 Forecast Assumptions and Methods – Immediate TSS Outcomes
3.5 Epidemiological Forecast of Cushing’s Syndrome (2013–2023)
3.5.1 Cushing’s Syndrome
3.5.2 Cushing’s Disease
3.5.3 Ectopic ACTH CS
3.5.4 Adrenal Adenoma CS
3.5.5 Adrenal Carcinoma CS
3.5.6 Age-Standardized Diagnosed Prevalence Rates
3.5.7 Immediate TSS Outcomes
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

Browse more reports on Therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com, +1 (888) 391-5441, [email protected]